通訊作者

• Ko FS, Yeh YK, Yen FS, Hwu CM. Deciphering the causal tapestry between cardiorespiratory fitness and type 2 diabetes mellitus. J Diabetes Investig. 2024 Jan 19. [IF 3.1]
• Kuo CS, Kuo NR, Yeh YK, Lee YJ, Chuang LM, Chen HF, Chen CC, Lee CC, Hsu CC, Li HY, Ou HY, Hwu CM. Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan Diabetes Registry Study. Lipids Health Dis. 2024 Jan 23. [IF 3.9]
• Yeh YK, Yen FS, Wei JC, Hu KC, Yu TS, Hsu CC, Hwu CM. Metformin and the risks of cellulitis, foot infections, and amputation in patients with type 2 diabetes. J Chin Med Assoc. 2024 Feb 26. [IF 3.0]
• Yen FS, Wei JC, Shih YH, Hung YT, Hsu TJ, Hsu CC, Hwu CM. Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study. Diabetes Metab Syndr. 2024 Aug 8. [IF 10.0]
• Yen YH, Yen FS, Ko FS, Wei JC, Huang Y, Yu TS, Hwu CM, Hsu CC. Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. 2024 Aug 29. [IF 5.4]
• Yen FS, Hsu CC, Wei JC, Tsai FJ, Huang Y, Yu TS, Hwu CM. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024 Oct 1. [IF 9.0]
• Lee CC, Ko FS, Yen FS, Hwu CM. LX9211, a rising star for relieving of diabetic Peripheral Neuropathic Pain. J Diabetes Investig. 2024 Nov 7. [IF 3.1]

共同通訊作者

• Yeh YK, Lin KH, Sheu WH, Lo SH, Yeh YP, Huang CN, Hwu CM*, Lu CH*. Determinants of Early Chronic Kidney Disease in Patients with Recently Diagnosed Type 2 diabetes mellitus: A retrospective study from the Taiwan Diabetes Registry. BMC Nephrology. 2024 Apr 15. [IF 2.3]

共同作者

• Suzuki K, Hatzikotoulas K, Southam L, Hwu CM, and , Zeggini E. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024 Feb 19. [IF 50.5]
• Fu-Shun Yen, Chii-Min Hwu, Jia-Sin Liu, Yi-Ling Wu, Keong Chong, Chih-Cheng Hsu. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease. Annals of internal medicine. 2024 Jun. [IF 39.2]
• Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus. Jama network open. 2024 June 12. [IF 13.8]
• Yen FS, Wei JC, Wu YL, Lo YR, Chen CM, Hwu CM, Hsu CC. Impact of family income on the development of gestational diabetes mellitus and the associated birth outcomes: A nationwide study. J Diabetes Investig. 2024 Nov 14. [IF 3.1]
• Hawkes G, ……, Hwu CM, …… Weedon MN. Whole-genome sequencing in 333,100 individuals reveals rare non-coding single variant and aggregate associations with height. Nat Commun. 2024 Oct 3. [IF 14.7]
• Yen FS, Wei JC, Lin SY, Hsu J, Yeh YK, Huang YH, Hsu TJ, Cho DY, Hwu CM, Hsu CC. The Impact of Pay-for-Performance Care on the Mortality and Cardiovascular Outcomes in Older Adults With Newly Diagnosed Type 2 Diabetes: A Nationwide Population-Based Cohort Study. J Am Med Dir Assoc. 2024 Dec 3. [IF 4.2]
• Low Birth Weight and Chronic Kidney Disease in Children. Nephrology Dialysis Transplantation. 2024 Dec 18. [Accept. IF: 4.8]
• SGLT-2 Inhibitors and the Risk of COPD Exacerbations and Mortality in COPD Patients. 2024 Dec 18. Annals of the American Thoracic Society [Accept. IF: 6.8]